SpectronRx
Reno, NV (US HQ); operations in US and Europe across 5 locations)
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (9)
○ EMA GMP
○ MHRA GMP
Quick Facts: SpectronRx
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Reno, NV (US HQ); operations in US and Europe across 5 locations)
- Modalities
- Ac-225, Lu-177, Radiopharmaceutical CDMO, Isotope production (accelerator-based), Radiolabeling, GMP hot-cell manufacturing, Sterile fill-finish
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About SpectronRx
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAc-225, Lu-177, Radiopharmaceutical CDMO, Isotope production (accelerator-based), Radiolabeling, GMP hot-cell manufacturing, Sterile fill-finish
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press9 articles
Broad modality coverage (7 modalities)
Recent News 9 articles
Telix unveils radiopharmaceutical spinoff Rhine Pharma following string of nuclear medicine acquisitions - Fierce Pharma
SpectronRx Receives Nuclear Materials License for New Indiana Facility - Contract Pharma
CDMO SpectronRx homes in on completion of European plant to crank out key radiopharma isotope - Fierce Pharma
SpectronRx’s New Medical Isotope Production Facility Produces Actinium-225 - Contract Pharma
SpectronRx to Showcase New Facility for the Global Supply of Actinium-225 at SNMMI 2022 - Business Wire
$85M Funding Drives SpectronRx’s Radiopharmaceutical Expansion - Medical Device and Diagnostic industry
SpectronRx raises $85 million to expand isotope production and manufacturing capacity - DOTmed
Drug substance maker raises prices due to energy crisis; SpectronRX gets $85M - Endpoints News
SpectronRx closes on $85M investment for further growth in Miami County - Inside INdiana Business
Frequently Asked Questions About SpectronRx
What is SpectronRx's CDMO Signal Score?
SpectronRx has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating SpectronRx for a manufacturing program?
Use the free AI matchmaker to compare SpectronRx against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
NorthStar Medical Radioisotopes
Beloit, WI
Ac-225, Cu-67, Lu-177, Radiopharmaceutical CDMO, Clinical and Commercial Dose Manufacturing
Evergreen Theragnostics
Springfield, NJ
Ac-225, At-211, Pb-212, Th-227, Lu-177, Alpha emitter radiopharmaceuticals, Clinical and Commercial GMP Manufacturing
PCI Pharma Services
Philadelphia, PA
Sterile fill-finish, Prefilled syringes, Cartridges, Vials, Lyophilization, ADC fill-finish, HPAPI, mRNA, Biologics, Oligonucleotides, Peptides
Curium
Paris, France
PET radiopharmaceuticals (F-18, Ga-68), SPECT diagnostics (Tc-99m), Therapeutic radiopharmaceuticals (Lu-177), Isotope production (Lu-177), Commercial-scale radiopharma manufacturing, Radiolabeling